Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

Verona Pharma plc
Posted on: 02 Aug 17

LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it will report its interim results for the six months ended June 30, 2017 on Tuesday, August 8, 2017.

Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Daylight Time (1:00 pm British Summer Time) on August 8, 2017 to discuss the interim financial results and provide a clinical development update.

Analysts and investors may participate in the conference call by utilizing the conference ID: 4729485 and dialing the following numbers:

  • (877)280-2296 or (646)254-3367 for callers in the United States
  • 0800 279 4841 or 44(0)20 3427 1905 for callers in the United Kingdom
  • 0800 589 2674 or 49(0)69 2222 10624 for calls in Germany

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of Verona Pharma's website at  www.veronapharma.com  and clicking on the webcast link.

A webcast replay of the conference call [audio] will be available on the "Investors" page of Verona Pharma's website at  www.veronapharma.com .

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com  
  
N+1 Singer (Nominated Adviser and UK Broker)Tel: +44 (0)20 7496 3000
Aubrey Powell / James White / Alex Laughton-Scott   
  
FTI Consulting (UK Media and Investor enquiries)Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert / 
Natalie Garland-Collins
veronapharma@fticonsulting.com  
  
ICR, Inc. (US Media and Investor enquiries) 
James HeinsTel: +1 203-682-8251
  James.Heins@icrinc.com  
Stephanie CarringtonTel. +1 646-277-1282
  Stephanie.Carrington@icrinc.com  


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire
HUG#2125136
GlobeNewswire
globenewswire.com

Last updated on: 03/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.